With the approval of $PFE 's encorafenib for metastatic CRC. This is the first BRAF inhibitor approved for mCRC. Other BRAFi are marketed by $RHHBY and $NVS  

#stocks #money #bio

See all approved BRAFi and their indications at https://t.co/ORLBaNPFMv